EJHaem. 2025 Feb 6;6(1):e1072. doi: 10.1002/jha2.1072. eCollection 2025 Feb.
ABSTRACT
BACKGROUND: A pilot clinical study of a Tax peptide-pulsed dendritic cell (DC) vaccine for adult T-cell leukaemia/lymphoma (ATL) indicated favourable clinical outcomes.
METHODS: We investigated its anti-tumour effect by T cell receptor (TCR) repertoire analysis in samples from an enrolled ATL patient who achieved a 10-year complete remission after DC vaccination.
RESULTS: In this patient, the dominant residual ATL clones that had persisted following previous treatment entirely disappeared within 3 years after DC vaccination. Additionally, the DC vaccine restored TCR repertoire diversity of normal T cells and newly induced functional Tax-specific CD8+ T cell clones.
CONCLUSIONS: The recovery of normal T cell immunity mediated by the DC vaccine may contribute to this long-lasting remission.
PMID:39917357 | PMC:PMC11800367 | DOI:10.1002/jha2.1072
